

65 4497

AUSTRALIA
PATENTS ACT 1990
NOTICE OF ENTITLEMENT

We, **Axis Research AS**, the applicant/Nominated Person in respect of
Application No. 83228/91 state the following:-

The Nominated Person is entitled to the grant of the patent
because the Nominated Person would, on the grant of a patent for
the invention to the inventor, be entitled to have the patent
assigned to the Nominated Person.

The Nominated Person is entitled to claim priority from the
applications listed in the declaration under Article 8 of the PCT
because the Nominated Person made the applications listed in the
declaration under Article 8 of the PCT, and because those
applications were the first applications made in a Convention
country in respect of the invention.

DATED this TWENTY SIXTH day of JANUARY 1993



.....
a member of the firm of
DAVIES COLLISON
CAVE for and on behalf
of the applicant(s)

(DCC ref: 1558988)



AU9183228

(12) PATENT ABRIDGMENT (11) Document No. AU-B-83228/91
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 654497

(54) Title
ANALYTE VARIANT ANALYSIS

International Patent Classification(s)
(51)⁵ G01N 033/68 G01N 033/538 G01N 033/561

(21) Application No. : 83228/91 (22) Application Date : 20.06.91

(87) PCT Publication Number : WO91/19983

(30) Priority Data

(31) Number	(32) Date	(33) Country
9013895	21.06.90	GB UNITED KINGDOM
9102024	30.01.91	GB UNITED KINGDOM

(43) Publication Date : 07.01.92

(44) Publication Date of Accepted Application : 10.11.94

(71) Applicant(s)
AXIS RESEARCH AS

(72) Inventor(s)
ERLING SUNDREHAGEN

(74) Attorney or Agent
DAVIES COLLISON CAVE , 1 Little Collins Street, MELBOURNE VIC 3000

(56) Prior Art Documents
AU 626563 38913/89 C07K 7/06
AU 18000/88 G01N 33/573

(57) Claim

1. A method of assessment of the concentration of a subset of variants in a population of proteinaceous analyte variants capable of separation by a fractionation system, wherein said population of variants is contacted with a population of labelled proteinaceous ^{specific for said population of variants} ~~specific~~ binding partners, ~~therefor~~ to form labelled binding partner-analyte complexes therewith, which are then subjected to separation by the said fractionation system into one or more fractions containing said subset of analyte variants in complexed form and assessment of the amount of label in one or more fractions so obtained, the said population of specific binding partners having, prior to reaction, substantially uniform distribution or mobility in said fractionation system.

2. A method as claimed in claim 1 wherein the specific binding partner for the analyte variant is an antibody or a fragment thereof.

(11) AU-B-83228/91
(10) 654497

-2-

5. A method as claimed in any one of claims 1 to 4 wherein the fractionation system is based on charge or isoelectric point.

6. A method as claimed in any one of claims 1 to 5 for the assessment of variants of transferrin.

7. A method as claimed in 6 wherein the fractionation system is selected from electrophoresis, ion exchange, chromatofocusing or isoelectric focusing.

OPI DATE 07/01/92 APPLN. ID 83228 / 91
 A0JP DATE 13/02/92 PCT NUMBER PCT/EP91/01145
 INTERNAT



REATY (PCT)

<p>(51) International Patent Classification ⁵ : G01N 33/68, 33/538, 33/561 // G01N 33/98</p>	<p>A1</p>	<p>(11) International Publication Number: WO 91/19983 (43) International Publication Date: 26 December 1991 (26.12.91)</p>
<p>(21) International Application Number: PCT/EP91/01145 (22) International Filing Date: 20 June 1991 (20.06.91) (30) Priority data: 9013895.9 21 June 1990 (21.06.90) GB 9102024.8 30 January 1991 (30.01.91) GB (71) Applicant (for all designated States except US): AXIS RE- SEARCH AS [NO/NO]; Helgenstr. 3, Grunerlokka, N- 0505 Oslo 5 (NO). (71)(72) Applicant and Inventor (for GB only): HOLMES, Mi- chael, John [GB/GB]; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB). (72) Inventor; and (75) Inventor/Applicant (for US only) : SUNDREHAGEN, Erl- ing [NO/NO]; Maridalsveien 52A, N-0458 Oslo 4 (NO).</p>		<p>(74) Agents: HOLMES, Michael, John et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB). (81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European pa- tent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European pa- tent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (Euro- pean patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p style="font-size: 2em; text-align: center;">654497</p>
<p>(54) Title: ANALYTE VARIANT ANALYSIS</p> <p>(57) Abstract</p> <p>The present invention provides a method of assessment of the concentration of a subset of variants in a population of pro- teinaceous analyte variants capable of separation by a fractionation system, wherein said population of variants are contacted with a population of labelled proteinaceous specific binding partners therefor to form labelled binding partner-analyte complexes therewith, which are then subjected to separation by the said fractionation system into one or more fractions containing said sub- set of analyte variants in complexed form and assessment of the amount of label in one or more fractions so obtained, the said population of specific binding partners having, prior to reaction, substantially uniform distribution or mobility in said fractiona- tion system, compositions and test kits for use in such methods. The method of the invention is particularly suitable for the analy- sis of variants of the protein transferrin.</p>		

ANALYTE VARIANT ANALYSIS

5 The present invention relates to a method of assessing the concentration of a subset of analyte variants within a group of different analyte variants, and to test kits and reagent compositions for use in such a method.

10 Biological molecules such as enzymes, antigens and other biologically important proteins frequently occur as a population of variants which, although sharing a common biological function or property e.g. antigenicity or enzymic activity, differ slightly in their structure.
15 This variance in structure may be due to differences in primary, secondary or tertiary structures in the amino acid sequences of proteins or polypeptides or to differences in the carbohydrate moieties or the lipid composition of the molecule. Although a common
20 characterising property or function between the variant molecules in a given population is retained, such differences in their structure often serves to alter other properties of the variants for example size, charge, isoelectric point (pI) which in turn alters
25 their behaviour in different fractionation and separation systems and may be used as the basis for separating one or more such variants in a variant mixture.

 Enzymes frequently occur as variants e.g.
30 isoenzymes and many other biological proteins are now known to exist in two or more variant forms, frequently differing in the extent of glycosylation of the protein or in the carbohydrate composition. The relative concentrations of such variants in a given body tissue
35 or fluid are generally constant but may be disturbed in certain diseases or pathological states or as a result of other disturbances to the body. Thus, for example

- 2 -

the ratio of glycosylated to non-glycosylated haemoglobins is known to increase in the serum of patients suffering from diabetes. Similarly certain structural proteins of analytical interest e.g.

5 myoglobins may have slight structural differences in different organs and may be released into the bloodstream following cell damage resulting from disease or injury.

Thus, by measuring the levels of the different
10 variants in the blood or other body tissue or fluid a diagnosis or assessment of the state of a disease or cellular damage can be made.

Of particular importance in this regard is the assessment of the levels of different variants of the
15 protein transferrin in the serum. Transferrin generally occurs in sialylated forms i.e. carrying three or more sialyl residues. However in chronic alcohol abusers, desialylated transferrin i.e. transferrin carrying two or less sialyl residues, is relatively increased in
20 content compared to non-alcoholics e.g. from a normal level of about 1-3% to about 6-25% of the total transferrin content of the patient's serum.

Desialylated transferrin, often termed carbohydrate deficient transferrin (CDT), is now generally regarded
25 as a clinically reliable marker for chronic alcoholism. However present methods of transferrin variant quantitation are time consuming and require advanced biochemical equipment. Thus, in the absence of a simple and convenient test for the desialylated transferrin
30 marker, chronic alcohol abuse is still presently diagnosed on the basis of clinical history, information from the patients themselves regarding their alcohol consumption, and a number of laboratory tests, all of which have limited sensitivity and specificity. Blood
35 alcohol level is a reliable measure only when blood is sampled within 24 hours after alcohol consumption. All present clinical chemistry tests have sensitivities and

- 3 -

specificities too low to reliably identify all alcohol abusers.

The microheterogeneity of transferrin and its correlation with alcohol abuse were first detected in 1980. (Stibler H, Sydow O, Borg S. "Quantitative estimation of abnormal microheterogeneity of serum transferrin in alcoholics". Pharmac. Biochem. Behav, 1980, 13 Suppl. 1,47-51). The clinical importance of this microheterogeneity has been further investigated, and isoelectric focusing and chromatofocusing methods for the quantitative separation of the different transferrin variants have been studied (Vesterberg O, Petren S. and Schmidt E.: "Increased concentrations of a transferrin variant after alcohol abuse". Clinical Chemica Acta, 141 33-39, 1984. Storey E.L., Mack U., Powell L.W. and Halliday J.W.: "Use of chromatofocusing to detect a transferrin variant in serum of alcoholic subjects". Clin. Chem. 31: 1543-1545, 1985). Joustra and Blanche filed in 1984 a method patent application in Sweden and Stibler, Borg and Joustra published in 1984 a mini column anion exchange chromatography method for quanti-filtration of carbohydrate-deficient transferrin in serum in relation to alcohol consumption. (Stibler H. Borg S. and Joustra M.: Alcoholism 10: 535-544, 1986. Joustra M. & Blanche C. Swedish patent application 8400587-5). These methods are based on isocratic ion exchange chromatography separation of the transferrin variants fractions in serum samples, followed by double antibody radioimmunoassay quantitation of the transferrin content of the different fractions. This ion exchange chromatography technique separates all transferrin components having 2 or less sialic acid residues which are thus isoelectrically above pH 5.65. Using this method 77 alcoholic patients could be clearly separated from 80 healthy "normal consumers" and 33 total abstainers by having elevated transferrin variants with isoelectric points (pI) above pH 5.65.

- 4 -

The main difficulty with these methods is that they are cumbersome and time-consuming to perform. A two-step procedure is necessary requiring a chromatographic separation of the transferrin variants in the serum samples, followed by an immunoassay quantification of the transferrin variants thus separated.

A need therefore exists for a reliable and simple assay for different analyte variants within a mixed population of analyte variants, and in particular for an improved method of detecting the different variants of transferrin.

Such analyte variants of clinical interest are normally proteinaceous in nature and frequently have an easily identifiable proteinaceous binding partner with which they form a complex. Most commonly the analyte variant is antigenic and the binding partner is therefore an antibody, although many proteins are specifically known to bind other proteins or peptides and may thus be regarded as binding partners. Thus for example the protein haptoglobin is a specific binding partner for haemoglobin. Such binding partners can be labelled, e.g. with an enzyme or other reporter atom or group and can then be used in assay procedures to label the analyte variants of interest.

The present invention is based on the concept that proteinaceous analyte variants can be labelled prior to separation using labelled binding partners so that after separation assessment of the label in the separated fractions provides a quantitative indication of the relative abundances of the variants. However, it has been found important that the analyte variants are reacted with a population of labelled binding partners which are reactive to all the different analyte variants to be analysed but have a substantially uniform distribution or mobility in a chosen fractionation or separation system.

Such a procedure is substantially simpler in

operation than prior systems using separation followed by conventional immunoassays on the separate fractions.

Thus in one aspect, the present invention provides a method of assessment of the concentration of a subset
5 of variants in a population of proteinaceous analyte variants capable of separation by a fractionation system, wherein said population of variants is contacted with a population of labelled proteinaceous ~~specific~~
specific for said population of variants binding partners, ~~therefor~~ to form labelled binding
10 partner-analyte complexes therewith, which are then subjected to separation by the said fractionation system into one or more fractions containing said subset of analyte variants in complexed form and assessment of the amount of label in one or more fractions so obtained,
15 the said population of specific binding partners having, prior to reaction, substantially uniform distribution or mobility in said fractionation system.

As used herein, the term "proteinaceous" is intended to include all molecules which are basically
20 protein in nature, including both peptides and polypeptides, but which may carry additional moieties of a non-protein nature e.g. lipid or carbohydrate groups.

Since the binding partner in the variant/binding partner complex exhibits a substantially uniform
25 distribution or mobility in the chosen fractionation system, the differences between the mobilities or distributions of the variant/binding partner complexes are due to the differences between the variants in those complexes, in other words, to the analyte variance. One
30 or more fractions of these variant/binding partner complexes thus obtained may be separated by the chosen fractionation system and the amount of label in each separated fraction assessed.

In a further aspect the invention also provides a
35 composition for performing the method of the invention comprising labelled proteinaceous binding partners e.g. antibodies or immunoreactive fragments thereof, which



have a substantially uniform mobility or distribution in one or more fractionation systems.

In a yet further aspect there is provided an analytical test kit comprising said composition together
5 with the reagents and/or materials required to perform the said fractionation.

Conveniently the analyte variants differ according to their charge in a given buffer system and thus may easily be separated by a charge-based system such as ion
10 exchange chromatography or electrophoresis.

Alternatively the analyte variants may differ in their isoelectric points (pI) and may be separated by isoelectric- or chromato-focusing. Thus for example the "Mono-P" column and "Polybuffer" chromatofocusing system
15 of Pharmacia, Sweden may be used. Isoelectric focusing of the complexes can take place in two-dimensional gel sheets, or alternatively the complexes may be separated by simple electrophoresis in agarose gel. A wide range of ion exchange media and solid phases may be used in
20 the method provided by this invention. The ionizable chemical residues on these media can be constituted by, but are not limited to, amine residues or sulphonated or carboxylated residues, and may be supported on beads, particles, gels, membranes, filters or any other
25 suitable solid phase. Although such fractionation systems are simple to use and give good results and are thus preferred according to the invention, any other fractionation system utilising a property in which the analyte is variant and in which the chosen binding
30 partner therefor is constant, may be used.

Resins or particles may be used in slurry batch forms or in columns. Columns may be eluted with salt or pH gradients or by isocratic elution. From a practical
point of view, slurry batch forms and isocratic elution
35 are preferred. Magnetizable particles were found to be especially advantageous. The ion exchange solid phase may also be constituted by a rigid three dimensional

structures or by ion exchange filters. If a filter is used, the filtration may be performed parallel to the surface, e.g. radially or along a filter strip.

Conveniently all or some of the various reagents
5 and components required to perform the separation step are supplied in kit form together with the labelled binding partner composition. As mentioned above this forms a further aspect of the invention.

Such reagents and materials generally include
10 buffer salts or solutions, surfactants e.g. Tween® and such like, preservatives e.g. sodium azide, the various gels, resins or other media required to perform the fractionation step, optionally ready assembled for use e.g. as columns etc.

15 As previously indicated, subsequent to the formation of the analyte variant/binding partner complexes, the complexes are isolated and the amount of label present in the complex fraction(s) is assessed.

Such labels may be constituted by any conventional
20 labelling system known in the art. Thus, the labels may be fluorescent, coloured, radioactive or enzymic and may be assessed by known means. Radioactive labels would generally be chosen from radioisotopes conventionally used in radioimmunoassay e.g. I^{125} , and many fluorescent
25 or coloured labels have been described. Thus suitable fluorescent labels include dimethylaminonaphthalene, fluorescein, dichlorotriazinyl-aminofluorescein or fluorescent metal compounds. Examples of coloured labels include 4-dimethylaminobenzene, 4-N,N-
30 dimethylaminoazobenzene, trinitrobenzene, benzofurazines, tetramethylrhodamine, texas red, morpholinorhodamine and derivatives thereof, azobenzenes, anthraquinones, oxazines, thiazines, triazines, porphyrins, phycobilins, chorophylls, indigo
35 dyes and analogs or derivatives thereof.

As mentioned above any proteinaceous binding partner for the analyte in question may be used provided

that it has uniform mobility or distribution in the chosen fractionation systems. Antibodies are generally preferred binding partners for antigens and haptens but other binding partner systems maybe employed to suit the situation e.g. haptoglobin-haemoglobin or hormone-receptor systems.

Immunoreactive antibody fragments e.g. F(ab) or F(ab')₂ fragments may also be used as long as the behaviour of the fragment in the given fractionation system remains uniform. Such fragments may usefully be S-blocked, for example with S-carboxymethyl groups.

F(v) fragments, that is the hypervariable regions of F(ab) fragments may also be used and may be of synthetic origin, via recombinant DNA technology or chemical synthesis.

We have found that where the molar amount of a labelled antibody or F(ab)₂ fragment is approximately equal to or in excess of that of the analyte, significant cross-linking occurs due to the divalent reactivity of the labelled reagent. This gives a low estimate of the number of analyte molecules. In many cases, therefore, it is preferred to use monovalent labelled analyte-binding partners, especially F(ab) or F(v) fragments of appropriate antibodies.

It should be noted that such monovalent fragments are likely to be subject to less variability, especially when produced synthetically, and if carefully labelled in a uniform manner, may not require a fractionation step in order to achieve the criterion of uniform mobility or distribution in the chosen fractionation system.

Hereinafter, for simplicity, references to 'antibodies' include fragments of antibodies unless stated otherwise.

The method of the invention is particularly suited to the analysis of levels of different variants of transferrin. Thus in a special embodiment this

- 9 -

invention provides a method for the assessment of variants of transferrin often named isotransferrins, in blood plasma, serum, whole blood or hemolysate. As previously mentioned, the transferrin variants differ
5 mainly in the different numbers of sialic acid residues on the transferrin molecules. The new method of the invention preferably comprises contacting the sample with a population of labelled antibodies reactive to human transferrin and having a substantially uniform
10 mobility or distribution in an fractionation system selected from electrophoresis, ion exchange, chromatofocusing or isoelectrofocusing. Preferably the antibody binding step takes place in a ferric ion-containing buffer solution allowing antigen-antibody
15 complexes to be formed. Such antigen-antibody reactions favourably take place close to neutral pH, preferably between pH 5 and pH 9, and at a salt concentration and composition not prohibiting such antigen-antibody complexes to be formed.

20 The labelled antibodies are preferably monoclonal antibodies but polyclonal antibodies may be used since the purification treatments described herein ensure uniform properties.

Labelled F(ab) or F(v) fragments of anti-
25 transferrin antibodies are novel substances of especial use in transferrin variant analysis. Even when relatively non-uniform, they are capable of giving better results than whole antibodies. Fractionated labelled F(ab) and F(v) fragments which are of uniform
30 mobility or composition in one or more fractionation systems are particularly preferred.

The transferrins of the sample may be saturated with ferric ions prior to or simultaneously with or subsequently to the exposure to the antibodies. Ferric
35 ion saturation of the transferrins prior to or simultaneously with the separation of the antigen-antibody complexes by means of the said separation systems is generally necessary for transferrin variant

analysis by this technology, since differences in the ferrous ion content of the variants will erase the distribution pattern in the said separation systems obtained due to the differences in sialic acid content.

5 The preferred method of the invention for transferrin variant analysis requires subjecting the mixture of variant/ antibody complexes to a chromatofocusing, ion exchange, electrophoresis or isoelectric focusing separation system. Since the
10 labelled antibodies have a substantially uniform mobility or distribution in one of these separation systems, these labelled antibodies form antigen-antibody complexes with the transferrin variants (isotransferrins) with differences in mobility or
15 distribution in one of the said separation systems corresponding to but not necessarily identical to, the mobility or distribution differences between the transferrin variants. Monoclonal antibodies reactive to human transferrin in general and having a substantially
20 uniform mobility or distribution in one of the said separation systems may be produced by conventional hybridoma techniques, and can be modified by chemical techniques if necessary. Purification of the desired antibodies is generally required and is preferably
25 achieved using one of the said systems e.g. by chromatofocusing, ion exchange chromatography, isoelectric focusing or electrophoresis.

 A test kit according to the invention for use in transferrin analysis preferably comprises labelled anti-
30 transferrin antibodies, or especially preferably labelled Fab fragments of such antibodies, together with at least one ferric ion salt or solution.

 In several embodiments of the method of this invention, labelled antibodies or other proteinaceous
35 binding partners with selected ranges of isoelectric points or exhibiting a special distribution or mobility in the said separation systems are preferred. To obtain

- 11 -

such modified proteins, the proteins may be modified prior to or after the labelling step. In general, such modifications will alter the number of charged groups, e.g. acidic or basic groups, in the molecule. Such
5 modification can be achieved by the use of reagents reacting with the side chains of the amino acids of the proteins, as described for example in Glazer, Delange and Sigman: "Chemical modification of proteins", Elsevier Biomedical Press, Amsterdam, New York, Oxford
10 1975, and other relevant literature. As an example, amine residues can be modified by carbamylation, acetylation, benzylation or succinylation, and carboxylic acid residues can be modified by esterification and coupling to nucleophiles by the use
15 of carbodiimides or other coupling agents. Similarly, the carbohydrate moieties of antibodies or other proteinaceous binding partners can be modified.

A convenient method for the modifications often necessary for the preparation of the labelled
20 glycoprotein binding partner compositions of this invention is the periodate oxidation of the carbohydrate moieties of glycoproteins followed by reaction of the resulting aldehyde with reagents introducing acidic or basic groups. Another convenient method appropriate to
25 proteins having disulphide bridges is the partial reduction of the disulphide bridges of cystine between the amino acid polypeptide chains of the proteins. Antibodies in particular contain several such disulphide linkages, and several, but not all, of the disulphide
30 linkages can be reduced to free thiols without compromising the affinity of the antibodies for the antigens. These linkages, and thus the resulting thiols, are located in the hinge region of the antibodies, remote from the antigen-binding sites of the
35 antibodies. 2-thioethanol and dithiothreitol are examples of such reducing agents, but not in a limiting sense. Following removal of the reducing agent,

reagents introducing acidic or basic groups are linked to the free thiols, by means of bifunctional coupling agents reacting with thiol moieties and nucleophilic moieties, e.g. sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, sulfosuccinimidyl(4-iodoacetyl) aminobenzoate or other succinimidyl-maleimide containing reagents, in a single or a two step procedure. Alternatively, the reagent introducing acidic or basic groups may be linked by means of substituted pyridyl disulfides or thiol-containing reagents reestablishing a disulfide linkage, but carrying a chemical moiety of acid or basic chemical properties.

In a special embodiment of the invention, the nucleophilic reagent can be constituted by an acid polymer, e.g. polypeptides with one or more acidic side chains on the amino acids.

The advantage of carbohydrate modification and/or modification by reduction of cystine in the hinge region is the minor interference with the antigen binding sites of the antibodies thus obtained. However, acidic polypeptides may also be linked to lysine residues or other residues of the polypeptide structure of the antibodies.

In the case of transferrin variant analysis transferrin variants carrying two or less sialic acid residues and having a pI value higher than the transferrin variants with three or more sialic acid residues, are of special interest. An embodiment of this invention uses anion exchange resins at a pH and buffering salt concentration and composition where the antigen-antibody complexes of transferrin variants with three or more sialic acid residues bind to the anion exchange solid phase, as opposed to the antigen-antibody complexes with transferrin variants having 2 or less sialic acid residues, which do not. In this embodiment, labelled antibodies, modified if necessary, which bind

- 13 -

to the anion exchange solid phase are preferred, thus leaving only in solution only the labelled antibody which has formed complexes with transferrin variants having 2 or less sialic acid residues. This is
5 illustrated schematically in Figure 1. The actual separation pH and buffer composition is chosen based upon the pI of the labelled monoclonal antibodies and complexes formed. After separation e.g. by
10 centrifugation or filtration if the solid phase is in slurry batch form, or by magnetic separation if the solid anion exchange phase is magnetizable or by elution if the solid phase is in a rigid or a column form, measurements of the label remaining in the solution are used to obtain an assessment of the concentration of the
15 antigen-antibody complexes, which correspond to the concentration of the transferrin variants having two or less sialic acid residues.

The method of this invention may be performed with labelled binding partners at a concentration in excess
20 of the total amount of analyte (all variants) or with the analyte in excess of the binding partners. When binding partners are used in excess, signals corresponding to the total concentration of the different variants are obtained. When analyte is
25 present in excess, signals corresponding to the relative amount of the different variants relative to the total concentration of all variants are obtained.

Where the labelled binding partner is to be used in excess, it is preferably monovalent. As indicated
30 above, divalent binding partners such as antibodies tend to cross-link to two separate analyte molecules especially when used in approximately equimolar quantities. Thus, for this purpose, F(ab) or F(v) fragments are preferred.

35 In the case of a binding partner system using antibodies or fragments thereof against antigen analytes, if an antigen excess is used, labelled

- 14 -

antibodies, modified if necessary, purified by means of affinity chromatography using immobilized antigens can optionally be used. Thus close to 100% of the antibodies or fragments can be immunoreactive, thus
5 reducing the fraction of free non-complexed antibodies or fragments in the assay to a very low level. In this way potential interference in the antigen variant analysis method can be reduced or avoided.

The advantage of this invention is the combination
10 of immunological quantitation and fractionation in one operation obtained by separating the complexes formed between the labelled binding partners and the different analyte variants followed by immunological quantitation. Thus this invention makes it possible to measure
15 transferrins and other analyte variants far more easily than in the prior art, particularly for the purpose of measuring transferrin variants with low sialic acid content in blood serum of plasma from persons undergoing investigations related to alcohol consumption.

20 The following Examples are provided to illustrate the invention in a non-limiting manner, with reference to the drawings in which:

Figure 2 represents an isoelectric focussing gel showing the pI of modified and labelled antibodies
25 against human transferrin;

Figure 3 shows graphically the separation of anti-transferrin FITC-derivatives by ion exchange chromatography on a strong anion exchange column (Buffer: 20 mM sodium phosphate pH 6.5). The solid line
30 indicates UV Absorbance at 280 nm, the dotted line the salt gradient (M NaCl);

Figure 4 shows graphically the further separation by re-chromatography on a strong anion exchange column, of 3 neighbouring fractions of anti-transferrin FITC
35 derivatives obtained from the preparation shown in Figure 2. (Buffer: 20 mM sodium phosphate pH 6.5);

Figure 5 shows graphically the fluorescence signals

- 15 -

of fractions of serum samples admixed with FITC-labelled anti-transferrin monoclonal antibodies, obtained from ion exchange chromatography (\square represents serum from an alcohol abuser, + serum from a non-drinker);

5 Figure 6 shown graphically the fluorescence signals of fractions obtained from ion-exchange chromatography of complexes of anti-transferrin monoclonal antibodies and disialo- (\square) and tetrasialo- (+) human transferrin;

10 Figure 7 shows graphically the results of preparative anion exchange chromatography of a labelled non-purified preparation of monoclonal anti-transferrin antibodies;

15 Figure 8 shows graphically the mobility in an anion exchange system of a single fraction obtained from the chromatography of Figure 7;

20 Figure 9 shows graphically the fluorescence of fractions of FITC-Fab-transferrin complexes from serum samples from a heavy drinker (- Δ -) and a normal subject (...O...) eluted from an anion exchange (mono Q) column.

EXAMPLE 1

From commercially available ascites produced in mice with a anti-transferrin IgG-producing hybridoma, 25 monoclonal antibodies were purified by means of ion exchange chromatography and gel chromatography in phosphate buffer. The immunoaffinity of the antibodies was assayed by a microtitre ELISA system using immobilized human transferrin and peroxidase-conjugated polyclonal anti-mouse-IgG antibodies in solution. The 30 purified antitransferrin antibodies were dialysed against 0.1 M acetic acid buffer of pH 5.6, and oxidized by periodate ions (50 mM final concentration). After the removal of the periodate ions by gel chromatography, 35 the antibodies were reacted with the acid polypeptide N-ala-ala-ala-ala-glu-glu-glu-glu-glu-COOH in 50 times molar excess to the antibodies followed by a

- 16 -

stabilization of the binding by means of cyanoborohydride ions in solution (final concentration = 15 mM). The resulting modified antibodies were dialysed against 0.1 M sodium carbonate buffer pH 9.5, and
5 reacted with 2-thioethanol at a final concentration of 10 mM for 30 minutes at room temperature, followed by removal of the 2-thioethanol by gel chromatography in phosphate buffer at pH 7.4. N-ala-ala-ala-ala-glu-glu-glu-glu-glu-COOH was reacted with the resulting free
10 thiols of the protein by means of sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, with molar ratios of 1:33:40 of antibody: coupling reagent: peptide. After subsequent dialysis against carbonate buffer, the modified antibodies were reacted with
15 fluorescein isothiocyanate, and subsequently purified by gel chromatography. At each step of these modifications, the antigen affinity was assayed, and only a very slight reduction was experienced. Figure 2 shows the results of isoelectric focusing performed in
20 gel electrophoresis (Phast System, Pharmacia), and exhibits the reduction in pI achieved. A substantial fraction of modified and labelled antibodies have a pI similar to or lower than the isotransferrins with two or less sialic acid residues. In this Figure (a) to (e)
25 indicate as follows:

- a) Human transferrin
- b) Unmodified monoclonal antitransferrin IgG
- c) Same as b), but where ala-ala-ala-ala-glu-glu-glu-glu-glu-glu has been coupled to the carbohydrate
30 moieties.
- d) Same as c), but where in addition ala-ala-ala-ala-glu-glu-glu-glu-glu has been coupled to the hinge region.
- 35 e) Same as d), but where fluorescein isothiocyanate has been reacted with the protein.

For the performance of the method of the present invention, a substantially uniform distribution or mobility of the antibodies in the relevant separation system is necessary. If not, the heterogeneity of the antibody complexes will make the separation and quantitation of the complexes of the antibodies with the different antigen variants impossible.

Figure 3 demonstrates the heterogeneity of modified monoclonal antibodies evaluated by preparative anion exchange chromatography. The dotted vertical bars indicate the collection of 20 fractions from this preparative anion exchange chromatography, to obtain fractions with a narrow pH range.

Figure 4 shows the results from an analytical chromatography of aliquots from three of the different neighbouring fractions obtained from the said preparative chromatography, demonstrating that close to uniform mobilities were obtained for each fraction. Even more uniform fractions can be obtained by the use of a less steep gradient profile in the elution, repetitive chromatographies or other chromatographic techniques. Alternatively or in combination, preparative isoelectric focusing or chromatofocusing may be used.

When the test sample is mixed with the said labelled monoclonal anti-human-transferrin antibodies having a uniform or close to uniform mobility or distribution, antigen-antibody complexes with different mobilities or distribution in the corresponding separation system are formed reflecting the differences between the transferrin variants. The different antigen-antibody complexes are separated by ion exchange chromatography, chromatofocusing or isoelectric focusing or electrophoresis or other chemical techniques utilizing

- 18 -

the differences in electric charge of the complexes formed.

EXAMPLE 2

5

Analysis of samples of sera from alcohol abusers and non-drinkers

Solid phase:

10

A 1 ml column of polystyrene particles with quaternary amine, substituted surface residues (Mono-Q column from Pharmacia, Uppsala, Sweden).

15

Eluent:

20mM bis-tris buffer with 100 mM sodium chloride, pH 6.50.

20

Procedure:

A 10 μ l serum sample was mixed with ferric citrate solution in 20 times molar excess to the transferrin content of the sample, followed by addition of monoclonal mouse antihuman transferrin antibodies, being reactive to all variants of human transferrin and having been modified and labelled with fluorescein and purified to having a very homogeneous mobility in the said ion exchange system - in a 1:1 molar concentration of the serum concentration of transferrin, and in the said eluent buffer. Subsequent to a short incubation at room temperature (5-10 minutes), the mixture was eluted through the column, followed by further elution with eluent buffer. 1.0ml fractions were collected and the fluorescence of the fractions was measured (Excitation 485 nm, Emmission 520 nm, measured on a Shimadzu

spectrophotometer RF-540). Figure 5 displays a typical pattern obtained with sera from alcoholics and non-drinkers. For comparison, a corresponding pattern obtained with samples of solution purified disialo- and tetrasialo transferrins instead of serum is shown in Figure 6.

EXAMPLE 3

10 Analysis of the antibody fraction used in Example 2

Figure 7 is a chromatogram displaying the results from preparative anion exchange chromatography of a labelled non-purified preparation of monoclonal antibodies from Example 2. From this chromatography fractions each of 0.5 ml were collected, and Figure 8 is a chromatogram illustrating how each fraction has a very narrow or homogeneous mobility in the anion exchange chromatography systems. Chromatography was performed on a Pharmacia Mono Q HR5 anion exchange column, equilibrated with 20 mM Tris buffer, pH 8.0 (Buffer A) and eluted using an elution gradient with Buffer B (Buffer A containing 0.7M NaCl).

25 EXAMPLE 4

Preparation of fluorescein-labelled monoclonal Fab-fragments having a substantially uniform mobility on an anion exchange matrix

30

From commercially available ascites produced in mice by established technology using an anti-transferrin IgG-producing hybridoma, monoclonal antibodies were purified by means of ion-exchange chromatography and subsequent size exclusion gel chromatography in a phosphate buffer. The buffer is then changed to a carbonate buffer before digesting the IgG antibodies to Fab antibody fragments by the use of papain in combination with dithiothreitol.

- 20 -

After this enzymatic modification free thiol groups (including free thiol groups on the antibody) are blocked with iodo-acetamide which also stops the enzymatic activity. The formed Fab fragments are
5 purified by a combination of dialysis and anionic exchange chromatography.

Purified antibody fragments (Fab) are dialyzed against a carbonate buffer pH 9.5 before modification with
10 fluorescein-isothiocyanate. Fluorescein binds to amino-groups on the antibody and fluorescein-labelled Fab is purified by size exclusion chromatography before finally isolating a fraction of labelled Fab from an anionic
15 exchange chromatography column. This fraction is characterized by having a high degree of homogeneity regarding the isoelectric point, thus having substantially uniform mobility on an anionic exchange matrix.

20 The immunoaffinity of the labelled Fab is tested by a micro-titre ELISA system using immobilized human transferrin and peroxidase-conjugated polyclonal anti-mouse-IgG antibodies in solution.

EXAMPLE 5

25

Preparation of AMCA-labelled monoclonal Fab-fragments having a substantially uniform mobility on an Anion exchange matrix

30 From commercially available ascites produced in mice by established technology using an anti-transferrin IgG-producing hybridoma, monoclonal antibodies were purified by means of ion-exchange chromatography and subsequent size exclusion gel chromatography in a phosphate buffer.
35 The buffer is then changed to a carbonate buffer before digesting the IgG antibodies to Fab antibody fragments by the use of papain in combination with dithiothreitol.

- 21 -

After this enzymatic modification free thiol groups (including free thiol groups on the antibody) are blocked with iodo-acetamide which also stops the enzymatic activity. The formed Fab fragments are
5 purified by a combination of dialysis and anionic exchange chromatography.

Purified antibody fragments are dialyzed against a borate buffer pH 8.0 before the addition of 7-amino-4-methyl-coumarin-3-acetic-acid-N-hydroxy-succinimide
10 (AMCA-NHS). AMCA-NHS is added from a DMSO solution and reacts with the free aminogroups of the Fab molecule. AMCA-Fab is purified by molecular size exclusion chromatography and finally by an anionic exchange
15 chromatography in order to achieve a fraction with a substantially uniform mobility in an anionic exchange matrix.

The immunoaffinity of the labelled Fab is tested by a
20 micro-titre ELISA system using immobilized human transferrin and peroxidase-conjugated polyclonal anti-mouse-IgG antibodies in solution.

EXAMPLE 6

25

Preparation of RESO-labelled monoclonal fab-fragments having a substantially uniform mobility in an anion exchange matrix

30 From commercially available ascites produced in mice by established technology using an anti-transferring IgG-producing hybridoma, monoclonal antibodies were purified by means of ion-exchange chromatography and subsequent size exclusion gel chromatography in a phosphate buffer.
35 The buffer is then changed to a carbonate buffer before digesting the IgG antibodies to Fab antibody fragments by the use of papain in combination with dithiothreitol.

- 22 -

After this enzymatic modification free thiol groups (including free thiol groups on the antibody) are blocked with iodo-acetamide which also stops the enzymatic activity. The formed Fab fragments are
5 purified by a combination of dialysis and anionic exchange chromatography.

Purified antibody fragment are dialyzed against a 0.1 M carbonate buffer pH 8.5. N-(Resorufin-4-carbonyl)-
10 piperidine-4-carboxylic-acid-N'-hydroxysuccinimide ester (RESOS) in a DMSO solution is added in molar excess and reacts with the amino-groups of the antibody under room temperature incubation. Labelled Fab is purified by a
15 molecular size exclusion column followed by anionic exchange chromatography. A fraction with substantially uniform mobility on the anionic exchange matrix is isolated.

The immunoaffinity of the labelled Fab is tested by a
20 micro-titre ELISA system using immobilized human transferrin and peroxidase-conjugated polyclonal anti-mouse-IgG antibodies in solution.

EXAMPLE 7

25

Assessment of desialylated transferrins in sera from patients

The test for desialylated transferrin is performed on
30 iron-saturated serum samples. Iron saturation is performed by adding 5 μ l FeCl_3 , 0.25 mg/ml, in a 0.2 M Tris-Maleate pH 7.0 solution to 20 μ l serum and incubation at room temperature for 20 min.

35 The test solution consist of 10.2 μ l iron-saturated serum added to 500 μ l 20 mM Tris-HCl, 70 mM NaCl, 0.05 % Tween-20, pH 8.0 containing 5×10^{-8} M FITC-Fab

- 23 -

(fluorescein-labelled anti-transferrin-Fab, according to Example 4 above). This solution is incubated for 15 min at room temperature before separation on a strong anionic exchange column. 500 μ l of the FITC-Fab-transferrin-complex-containing solution is separated by elution with 20 mM TRIS-HCl, 70 mM NaCl, 0.05% Tween, pH 8.0 on a MonoQ (Pharmacia) column. Fig. 9 Shows the results of elution of FITC-Fab-transferrin complexes from serum samples from a heavy drinker and a normal subject. The fluorescence in fraction 1 represents unbound Fab, the fluorescence in fractions 3-7 represents FITC-Fab bound to desialylated transferrin and fluorescence in fractions greater than 9 represents FITC-Fab bound to normal transferrin. Differences in fluorescence in fractions lower than no. 7 discriminate between heavy alcohol consumers and individuals not abusing alcohol.

EXAMPLE 8

Assessment of desialylated transferrins in sera from patients using disposable minicolumns

Disposable columns are prepared from strong anionic exchange gel (Q-Sepharose, Pharmacia) by using 0.5 ml of the gel in a column with inner diameter 0.7 cm. The column is equilibrated with 20 mM Tris-HCl, 70 mM NaCl, 0.05 % Tween-20, pH 8.0.

The test on the minicolumn for desialylated transferrin is performed on iron-saturated serum samples. Iron saturation is performed by adding 5 μ l FeCl_3 0.25 mg/ml in a 0.2 M Tris-Maleate pH 7.0 solution to 20 μ l serum and incubation at room temperature for 20 min.

The test solution consists of 10.2 μ l iron-saturated serum added to 500 μ l 20 mM Tris-HCl, 70 mM NaCl, 0.05 %

- 24 -

Tween-20, pH 8.0 containing 5×10^{-8} M FITC-Fab (fluorescein-labelled anti-transferrin-Fab, according to Example 4 above). This solution is incubated for 15 min at room temperature before separation on a strong anionic exchange column. 100 μ l of the FITC-Fab-transferrin-complex-containing solution is added to the column and 3.0 ml of 20 mM Tris-HCl, 70 mM NaCl, 0.05 % Tween-20, pH 8.0 is used to elute the desialylated transferrin-FITC-Fab complexes. The total eluate is collected and the fluorescence from fluorescein is measured and compared a standard dilution of the fluorescein-labelled Fab fragments used. The results are used to discriminate between heavy alcohol consumers and individuals not abusing alcohol.

The tables contains results from several heavy alcohol consumers and normals.

TABLES

Serum	Ethanol use	Measured fluorescence % of Total
A	Alcohol abusers	10.9
B		8.5
C		8.4
D		7.8
E	Non-abusers	5.2
F		4.8
G		4.8

EXAMPLE 9A test for desialylated transferrin (CDT) in serum (1)

5 MATERIALS

i. Solution A: 150 kBq/ml ^{125}I -antitransferrin-Fab, 20 mM bis-TRIS, 3.7×10^{-5} M Fe^{3+} -citrate, 66 mM NaCl, 5.9 mM HCl, 3.1 mM Na-azide, 0.05 % Tween 20, pH 7.0.

ii. Solution B: 20 mM bis-TRIS, 55 mM NaCl, 5.9 mM HCl, 3.1 mM Na-azide, 0.05 % Tween 20, pH 7.0.

15 iii. Columns for separation: 0.5 ml strong anion-exchange gel (Q-Sepharose Fast Flow, Pharmacia) equilibrated with solution B.

iv. Test tubes

20

Reagents and columns are stored at 4-8°C for longer periods of time.

Solutions and columns are equilibrated to room temperature before use.

25

PROCEDURE

1: TEST SOLUTION PREPARATION

30

1.1: 30 μl serum is added to 220 μl Solution A in a test tube. Only ordinary serum samples are used.

1.2: The samples are incubated for 1-10 min. at room temperature.

35

2: COLUMN SEPARATION

2.1: The column is emptied of surplus solution by removing first the top and thereafter the bottom
5 stopper. The solution is allowed to elute through the column and the eluate is discarded.

2.2: A tube is placed beneath the column.

2.3: 200 μ l test-solution is added. Care is taken to
10 add the test sample directly to the top filter in the column. The sample is allowed to sink into the top filter before eluting by adding 3.0 ml Solution B. The column is eluted until elution stops.

3: MEASUREMENT

15

3.1: The collected solution is measured by gamma-counting.

3.2: A reference curve is established based upon
20 reference samples containing known % percentages of CDT.

3.3: % CDT in unknown serum samples are calculated using the reference curve.

EXAMPLE 10

25

A test for desialylated transferrin (CDT) in serum (2)

MATERIALS

30 i: Solution A: 0.14 mg/ml fluorescein-labelled-antitransferrin-Fab, 5 mM TRIS, 55 mM NaCl, pH 8.0, 3.1 mM sodium azide.

ii: Solution B: 20 mM bis-TRIS, 3.7×10^{-5} M Fe^{3+} -citrate,
35 66 mM NaCl, 5.9 mM HCl, 3.1 mM Na-azide, 0.05 % Tween 20, pH 7.0.

- 27 -

iii: Solution C: 20 mM bis-TRIS, 66 mM NaCl, 5.9 mM HCl, 3.1 mM Na azide, 0.05 % Tween 20, pH 7.0.

iv: Solution D: 1.0 M TRIS-base, 3.1 mM Na azide.

5

v: Columns for separation: 0.5 ml strong anion exchange gel (Q-Sepharose Fast Flow, Pharmacia) equilibrated with solution C.

10 vi: Test tubes

Reagents and columns are stored at 4-8°C for longer periods of time.

15 Solutions and columns are equilibrated to room temperature before use.

Solution A and solutions containing A should be protected from light.

20

PROCEDURE

1: DAILY PREPARATION OF INCUBATION SOLUTION

25 1.1: Solution B is mixed with Solution A by mixing

1 part Solution A with
10 parts Solution B

1.2: Incubation solution is prepared sufficient for one day's testing only. A minimum of 230 μ l is needed for each test, plus 20 μ l for reference measurement.

30

2: TEST PREPARATION

35

2.1: 30 μ l serum is added to 220 μ l Incubation solution (see above) in a test tube. Only ordinary serum

- 28 -

samples should be used.

2.2: The samples are incubated for 1-10 minutes at room temperature.

5 3: COLUMN SEPARATION

3.1: The column is emptied of surplus solution by removing first the top and thereafter the bottom stopper. The solution is allowed to elute through
10 the column and the eluate discarded.

3.2: A Cuvette is placed beneath the column.

3.3: 200 μ l test-solution is added. Care is taken to
15 add the test sample directly to the top filter in the column. The sample is allowed to sink into the top filter before eluting by adding 3.0 ml Solution C. Elution is continued until it stops.

20 3.4: 0.1 ml Solution D is added to the collected eluate and mixed by inverting the cuvette.

4: MEASUREMENT

25 4.1: The collected solution is measured by fluorescence. Excitation 485 nm (range 480-490) and emission 520 nm (range 515-525).

4.2: Sample for Zero setting:
30 3.0 ml Solution C +
 0.1 ml Solution D.

4.3: The % CDT in an unknown sample can be determined from a standard curve established by measurement of
35 standard sera.

EXAMPLE 11Fractionation in batch format5 Assay solution:

300 μ l 20 mM Bis-Tris with 50 mM NaCl and 0.05% Tween,
pH 7.0 + 1.3 μ l 50 mM tris maleate 9.25 mmol/l Fe^{3+} -
citrate + 9 μ l of a solution comprising 0.5 μ g
10 fluorescein labelled FAB fragments.

Particles:

AQ quaternary amine particles from Dyno Particles,
15 Norway.

PROCEDURE:

1. To the assay solution, a 4 μ l serum sample is
20 added.
2. A particle suspension in 20 mM Bis-Tris buffer with
50 mM NaCl_2 and 0.05% Tween, pH 7, is added to a
final volume of 40 vol. % particle suspension, and
25 the suspension is agitated for 10 minutes, followed
by centrifugation at 1500 g for 5 minutes.
3. The fluorescence of the supernate is measured.

EXAMPLE 12Fluorescence labelling of antibody Fab-fragments

- 5 1. 2.5 mg Fab in 50 mM carbonate-buffer pH 9.5 is
added to 25 μ g fluorescein-isothiocyanate (FITC).
FITC is prepared from FITC on celite (10%)
dissolved in dimethyl-sulphoxide.
- 10 2. The Fab and FITC solution is incubated in room
temperature in the dark for 18-24 hours.
- 15 3. Fluorescein-Fab is purified by molecular size gel-
chromatography (Superose 6 PrepGrade, Pharmacia,
1,30cm). The labelled Fab-fragment is eluted by a
10 mM Na-phosphate, 0.5 M NaCl, pH 7.4 buffer. The
Antibody fraction is isolated.
- 20 4. The collected fluorescein-Fab solution is buffer-
changed to 2.5 mM TRIS-HCl, pH 8.0 and further
processed by strong anionic exchange
chromatography.

25 The above procedure has been used to label Fab fragments
obtained from monoclonal antibodies reactive against all
variants of transferrin. Anti-transferrin antibodies
(IgG) were purified from commercially available ascites,
the IgG molecules were digested using papain and the
free thiol groups thereby formed were blocked using
30 iodoacetamide following conventional procedures. The
resulting Fab fragments were purified by anion exchange
chromatography and were then subjected to the labelling
procedure set out above.

EXAMPLE 13Iodine-¹²⁵I-labelling of antibody Fab-fragments

- 5 1. 5 mCi ¹²⁵I-Bolton Hunter reagent dissolved in
 benzene is evaporated to dryness by the use of
 nitrogen-gas.
 2. 0.65 mg Fab dissolved in 0.1 M borate solution pH
10 8.5, volume 0.96 ml is added to the ¹²⁵I-Bolton-
 Hunter reagent and incubated/shaken on ice for 30
 min.
 3. 50 mM glycine in 0.1 M borate, pH 8.5, 0.5 ml is
15 added to stop the reaction. The solution is
 further incubated on ice for 10 min.
 4. The reaction solution is then chromatographed on a
 size exclusion column (Superose 6 PrepGrade,
20 Pharmacia, 1x30cm). The labelled Fab-fragment is
 eluted by a 10 mM Na-phosphate, 0.1 M NaCl, pH 7.4
 buffer. The antibody fraction is isolated.
 5. Isolated ¹²⁵I-Fab is buffer changed to 2.5 mM TRIS-
25 HCl, pH 8.0 by ultracentrifugation with molecular
 cut-off 10,000 and concentrated to 1.5 ml.
 6. Further processing is by strong ion-exchange
 chromatography.
 - 30
- Anti-transferrin Fab fragments, obtained as described in
Example 12 were labelled using the above procedure.

CLAIMS:

1. A method of assessment of the concentration of a subset of variants in a population of proteinaceous
5 analyte variants capable of separation by a fractionation system, wherein said population of variants is contacted with a population of labelled proteinaceous ^{specific for said population of variants} ~~specific~~ binding partners, ~~therefor~~ to form
10 labelled binding partner-analyte complexes therewith, which are then subjected to separation by the said fractionation system into one or more fractions containing said subset of analyte variants in complexed form and assessment of the amount of label in one or
15 more fractions so obtained, the said population of specific binding partners having, prior to reaction, substantially uniform distribution or mobility in said fractionation system.
2. A method as claimed in claim 1 wherein the specific
20 binding partner for the analyte variant is an antibody or a fragment thereof.
3. A method as claimed in claim 1 or claim 2 wherein
25 the specific binding partner is monovalent.
4. A method as claimed in claim 3 wherein the specific
binding partner is a F(ab) fragment of an antibody.
5. A method as claimed in any one of claims 1 to 4
30 wherein the fractionation system is based on charge or isoelectric point.
6. A method as claimed in any one of claims 1 to 5 for
the assessment of variants of transferrin.



7. A method as claimed in 6 wherein the fractionation system is selected from electrophoresis, ion exchange, chromatofocusing or isoelectric focusing.

5 8. A method as claimed in claim 6 or claim 7 additionally comprising saturating the population of transferrin variants with ferric ions prior to or simultaneously with the separation step.

10 9. A method as claimed in any one of claims 1 to 8 wherein substantially uniform distribution or mobility of the specific binding partner population in said fractionation system is obtained by modification and/or fractionation.

15 10. A method as claimed in any one of claims 1 to 9, wherein the population of analyte variants is present in excess of the binding partner population, whereby an assessment of the relative amounts of one or more
20 different variants relative to the total concentration of all variants, is obtained.

25 11. A composition, ^{when used} ~~for use~~ in the method of any one of claims 1 to 10 comprising labelled proteinaceous binding partners for the analyte of interest, said binding partners having a substantially uniform mobility or distribution in one or more fractionation systems based on charge or isoelectric point.

30 12. A composition as claimed in claim 11 comprising labelled F(ab) or F(v) fragments of anti-transferrin antibodies.

35 13. An analytical test kit, ^{when used in the method of any one of claims 1 to 10,} comprising a composition as claimed in claim 11 or claim 12 together with the reagents and/or materials required to perform the said fractionation.



14. An analytical test kit as claimed in claim 13
comprising a composition as claimed in claim 11 or claim
12, together with a fractionation medium and one or more
agents selected from buffer salts or solutions,
5 surfactants and preservatives.

15. An analytical test kit as claimed in claim 14 for
use in the assessment of variants of transferrin further
comprising at least one ferric ion salt or solution.
10

Dated this 13th day of April, 1994

Axis Research AS
By its Patent Attorneys
Davies Collison Cave

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
21

1/3





Figure 1

2/3

Figure 2



3/3




Fig. 3

4/3




Fig. 4

5/3




Figure 5

6/3

Figure 6




Figure 7

7/9






Figure 8




3/3

Figure 9



INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 91/01145

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 G 01 N 33/68 G 01 N 33/538 G 01 N 33/561 // G 01 N 33/98		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	G 01 N	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	CLIN. CHEM., vol. 31, no. 9, 1985, E.L. STOREY et al.: "Use of chromatofocusing to detect a transferrin variant in serum of alcoholic subjects", pages 1543-1545 (cited in the application) ---	
A	CLINICA CHIMICA ACTA, vol. 141, no. 1, 15 August 1984, Elsevier Science Publishers B.V., O. VESTERBERG et al.: "Increased concentrations of a transferrin variant after alcohol abuse", pages 33-39 (cited in the application) ---	
A	WO,A,8503578 (PHARMACIA AB) 15 August 1985 & SE,A,440699 (cited in the application) --- -/-	
¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
16-09-1991		
International Searching Authority	Signature of Authorizing Officer	
EUROPEAN PATENT OFFICE	21.10.91  M.M. van der Drift	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,A	<p>BLUTALKOHOL, vol. 27, no. 6, November 1990, P.W.M. REISINGER et al.: "Die Diagnose von Alkoholismus auf der Grundlage des Nachweises einer Transferrinvariante durch Polyacrylamid-Gelelektrophorese und Immunoblotting" -----</p>	

EP 9101145
SA 48360

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

EPO FORM 70479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82